Cervera / Piette / Shoenfeld The Antiphospholipid Syndrome II

Autoimmune Thrombosis
1. Auflage 2002
ISBN: 978-0-08-052730-7
Verlag: Elsevier Reference Monographs
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 478 Seiten

This book provides the reader with a comprehensive overview of the Antiphospholipid syndrome. One of the most important advances in rheumatology and connective tissue diseases of the last decade. It provides an explanation for many previously undefined conditions with no clear pathogenesis encompassing all subspeculations in internal medicine as well as obstetrics. Clotting problems leading to strokes and myocardial infarctions (in younger people) as well as a large variety of other syndromes such as chorea, hyproadrenalism, pulmonary problems are now being understood.

Autoren/Hrsg.

Cervera, R.

Piette, J.C.

Shoenfeld, Y.

Shoenfeld, Yehuda

Inhaltsverzeichnis

1;Cover;1
2;Contents;16
3;Preface;6
4;Editor biography;8
5;List of Contributors;12
6;Part I: History and Epidemiology of the Antiphospholipid Syndrome (Editor: Ronald A. Asherson);22
6.1;Chapter 1. Milestones in the Antiphospholipid Syndrome;24
6.2;Chapter 2. Classification and Epidemiology of the Antiphospholipid Syndrome;32
7;Part II: Immunology and Pathophysiology of the Antiphospholipid Syndrome (Editor: Yehuda Shoenfeld);42
7.1;Chapter 3. Lupus Anticoagulant: Detection, Standardization and Heterogeneity;44
7.2;Chapter 4. Antibodies to Cardiolipin and other Phospholipids;50
7.3;Chapter 5. ß2-Glycoprotein I and anti-ß2-Glycoprotein I Antibodies;66
7.4;Chapter 6. Anti-Prothrombin Antibodies;80
7.5;Chapter 7. The Annexins: A Target of Antiphospholipid Antibodies;92
7.6;Chapter 8. Antiphospholipid/Endothelial Cell Interaction in the Pathogenesis of the Antiphospholipid Syndrome;100
7.7;Chapter 9. Tissue Factor, Protein C pathway and other Hemostasis Abnormalities in the Pathogenesis of the Antiphospholipid Syndrome;112
7.8;Chapter 10. Systemic Involvement in the Antiphospholipid Syndrome: Lessons from Animal Models;122
7.9;Chapter 11. Cytokines, Th1/Th2 and Adhesion Molecules in the Antiphospholipid Syndrome;128
7.10;Chapter 12. Lessons from Monoclonal Antiphospholipid Antibodies;134
7.11;Chapter 13. Immunogenetics of the Antiphospholipid Syndrome;140
7.12;Chapter 14. Pathology of the Antiphospholipid Syndrome;152
7.13;Chapter 15. Antiphospholipid Antibodies in Human and Murine Atherogenesis;158
8;Part III: Clinical Features in the Antiphospholipid Syndrome (Editor: Ricard Cervera);164
8.1;Chapter 16. Thrombotic Manifestations in the Antiphospholipid Syndrome;166
8.2;Chapter 17. Neurologic Manifestations in the Antiphospholipid Syndrome;176
8.3;Chapter 18. Cardiac and Pulmonary Manifestations in the Antiphospholipid Syndrome;190
8.4;Chapter 19. Renal, Hepatic and other Intra-abdominal Manifestations in the Antiphospholipid Syndrome;210
8.5;Chapter 20. Fetal and Obstetric Manifestations and Infertility in the Antiphospholipid Syndrome;226
8.6;Chapter 21. Osteo-articular Manifestations in the Antiphospholipid Syndrome;234
8.7;Chapter 22. Ophthalmic and Otological Manifestations in the Antiphospholipid Syndrome;242
8.8;Chapter 23. Dermatologic Manifestations in the Antiphospholipid Syndrome;256
8.9;Chapter 24. Endocrine Manifestations in the Antiphospholipid Syndrome;266
8.10;Chapter 25. Hematological Abnormalities in the Antiphospholipid Syndrome;280
8.11;Chapter 26. Immunological Abnormalities in the Antiphospholipid Syndrome;292
8.12;Chapter 27. "Primary", "Secondary", "Seronegative", "Catastrophic" and other Subsets of the Antiphospholipid Syndrome;306
8.13;Chapter 28. Pediatric and Familial Antiphospholipid Syndrome;318
8.14;Chapter 29. Antiphospholipid Antibodies and Malignancies;338
8.15;Chapter 30. Antiphospholipid Antibodies and Vasculitis;352
8.16;Chapter 31. Antiphospholipid Antibodies and Infections-Drugs;364
9;Part IV: Management and Prognosis of the Antiphospholipid Syndrome (Editor: Jean-Charles Piette);380
9.1;Chapter 32. Management of Thrombosis in the Antiphospholipid Syndrome;382
9.2;Chapter 33. Management of Reproductive Failure in the Antiphospholipid Syndrome;396
9.3;Chapter 34. Management of the Difficult Aspects of the Antiphospholipid Syndrome;416
9.4;Chapter 35. Course and Prognosis of the Antiphospholipid Syndrome;430
9.5;Chapter 36. Novel Perspectives in the Treatment of the Antiphospholipid Syndrome–from Anticoagulation to Immunomodulation;442
10;Part V: Appendix;450
10.1;Chapter 37. The Antiphospholipid Syndrome in the Internet;452
10.2;Chapter 38. A Patient's Guide to the Antiphospholipid Syndrome;458
11;Subject Index;466